Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'
Fluor FLR is "always a bridesmaid, never a bride," Cramer said. On the earnings front, Fluor, on May 2, posted mixed first-quarter 2025 results, with key metrics surpassing some expectations. Fluor's revenue grew 6.6% year-over-year to 4.18 billion. Adjusted EPS improved to 73 cents from 47 cents a year ago, above the consensus of 50 cents. Price Action: On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Dover Corporation DOV. Supporting his view, ...